Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02929797

Acronym

AKT

Enrollment

Registered

2016-10-11

Start date

2016-08-31

Completion date

2019-08-31

Last updated

2016-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Ductal Adenocarcinoma

Keywords

pancreatic cancer

Brief summary

A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.

Interventions

BIOLOGICALCD8+NKG2D+ AKT Cell

AKT: CD8+NKG2D+ AKT cell

DRUGGemcitabine

gemcitabine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* 1\. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology; * 2\. Pancreatic cancer after radical resection; * 3\. Eastern Cooperative Oncology Group Performance Status less than 2; * 4\. Without radiotherapy or neoadjuvant chemotherapy; * 5\. The man or the gestation and lactation women Age between 18 to 80 years old; * 6\. Bone marrow functioned well: ANC more than 1.5\*10\^9/ L, PLT more than 100\*10\^9/LHgb more than 9 g/dL; * 7\. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN, TBIL less than 1.5 ULN; * 8\. PT and PPT are in normal ranges; * 9\. Three months prior to clinical research did not receive any other clinical research trials; * 10\. patients are voluntary, and willing to sign informed consent.

Exclusion criteria

* 1\. Patients with other malignant tumors in the past five years; * 2\. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment; * 3\. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection; * 4\. Known allergy to any kind of component of study drugs; * 5\. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis); * 6\. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy; * 7\. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements; * 8\. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	1 year

Secondary

Measure	Time frame
Overall Survival	3 years
immune indices	1 year
Quality of life	3 years

Countries

China

Contacts

Primary Contacthongxia Wang, Dr.

whx365@126.com8621-63240090

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026